Clinical trial NCT02727361: Role of the Striatal Cholinergic System in the Pathophysiology of Dystonia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dystonia
Keywords: Dystonia
Binding potential
FEOBV
Lead sponsor: University Hospital, Bordeaux
Sponsor class: OTHER
First posted: 2016-04-04
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Dystonia is defined as a syndrome of sustained muscle contractions resulting in repetitive movements and abnormal postures. DYT1 is the most common form of genetic dystonia, but the link between genomic mutations and phenotypic expression remains largely unknown. Furthermore, secondary forms of dystonia have highlighted the role of the basal ganglia, particularly the putamen in the pathophysiology of the disease. Experimental results in a genetic model of dystonia in rodents suggest that cholinergic inter-neurons (ACh-I) of the putamen play a critical role in the pathological process of plasticity in the cortico-striatal synapse. However, these results have not been demonstrated in humans.

Detailed description: The purpose of this study is to demonstrate that the phenotype of dystonia is associated with the degree of striatal ACh-I alterations.

In this molecular imaging study, the investigators will directly test this hypothesis using a PET radiotracer of the vesicular acetylcholine transporter (VAT). Their goal is to explore the relationships between cholinergic dysfunction and clinical disease expression and the associated morphological and functional alterations. The experimental protocol will also include multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).

Eligibility criteria: Inclusion Criteria:

* Man or woman 18 to 75 years, with health insurance European health insurance card (for resident patients in EU), insurance by bilateral social security agreement signed between his country and France (for resident patients outside the EU)
* Diagnosis of dystonia DYT1 confirmed by molecular biology (TORSINE- A gene mutation)
* Patient who stopped his anticholinergic treatment 48 hours before imaging

Exclusion Criteria:

* Patients who underwent surgery for deep brain stimulation or under cholinergic treatment.
* Presence of a counter-indication for MRI
* Presence of a counter-indication for TEP Scan with \[18F\]-FEOBV
* Woman premenopausal without effective ongoing contraception (intrauterine device or combined hormonal)
* Patient who underwent a PET examination in the previous month
* Presence of any health problem preventing travel to the imaging service of the University Hospital
* Being under the legal guardianship of another person or being unable to provide consent to participate
* Pregnant or breastfeeding woman

Primary outcomes:
measure: Binding potential
timeFrame: Inclusion (V0)
Secondary outcomes:
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: CHU de Bordeaux
Study officials:
affiliation: University Hospital, Bordeaux
name: FERNANDEZ Philippe
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Bordeaux
name: BURBAUD Pierre
role: STUDY_CHAIR
References: